ELOX Eloxx Pharmaceuticals, Inc. - Common Stock
NASDAQ · Ver en SEC EDGAR ↗ cerrar Oct 2, 2026 10-K/10-Q Ago 11, 2026
$15,51
· % del rango de 52 semanas
· por encima del mínimo
· a alto
$8,20mínimo 52 semanas
$23,40máximo 52 semanas
Capitalización Bursátil (MRQ)
$63M
BPA
$-0.49
Ingresos
$0
tus insignias
Rango 52S
$8–$23
Calificación del Analista
BUY
Precio Objetivo
$38
P/E
·
ROE
30.1%
Margen de Beneficio Neto
·
Tu barra de insignias está vacía — fija una métrica en cualquier lugar de esta página.
ELOX Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas
Precio
$15.51
Capitalización Bursátil (MRQ)
$63M
BPA
$-0.49
Ingresos
$0
ROE
30.1%
Deuda/Capital (MRQ)
0.0
Rango 52S
$8–$23
ELOX Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista
rango
barras
La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.
Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA
Ingresos$02023-12-31 → 2025-12-31
BPA$-0.492021-12-31 → 2025-12-31
Flujo de caja libre·2017-06-30 → 2022-12-31
Valoración y ratios
Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?
| Métrica | Tendencia a 5 años | ELOX | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| P/C (MRQ) | 1.3 | · | · | · |
La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.
Rentabilidad Márgenes brutos, operativos y netos; ROE, ROA, ROIC
| Métrica | Tendencia a 5 años | ELOX | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| ROA | -145.4%promedio 5A ≈-146.9% | ≈-146.9% | · | · | |
| ROE | 30.1%promedio 5A ≈83.4% | ≈83.4% | · | · | |
| ROIC | 59.0%promedio 5A ≈-655.6% | ≈-655.6% | · | · |
Salud financiera Deuda, liquidez, solvencia — solidez del balance general
| Métrica | Tendencia a 5 años | ELOX | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Deuda / Patrimonio (MRQ) | 0.0promedio 5A ≈-0.2 | ≈-0.2 | · | · | |
| Ratio corriente (MRQ) | 3.7promedio 5A ≈1.8 | ≈1.8 | · | · | |
| Quick Ratio (Ratio Rápido) | 0.3promedio 5A ≈1.8 | ≈1.8 | · | · | |
| Long-Term Debt / Equity (Deuda a Largo Plazo / Patrimonio) | 0.0promedio 5A ≈-0.1 | ≈-0.1 | · | · |
Crecimiento Crecimiento de ingresos, BPA y beneficio neto: interanual, CAGR a 3 años, CAGR a 5 años
Aún no hay datos para este grupo de ratios
Aún no hay datos fundamentales para este ticker.
Eficiencia de capital Rotación de activos, rotación de inventario, rotación de cuentas por cobrar
| Métrica | Tendencia a 5 años | ELOX | promedio 5A | Mediana de Pares | Veredicto |
|---|---|---|---|---|---|
| Asset Turnover (Rotación de Activos) | 0.0 | · | · | · | |
| Revenue / Employee (Ingresos / Empleado) | ≈$0.00 | · | · | · |
valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana
Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados
Sorpresa Media
1.3%
| Período | Informe | EPS Actual | EPS est. | Sorpresa |
|---|---|---|---|---|
| 30 de septiembre de 2023 | $-14.41 | $-22.10 | 34.8% | |
| 30 de junio de 2023 | $-21.56 | $-17.28 | -24.8% | |
| 31 de marzo de 2023 | $-31.68 | $-28.61 | -10.7% | |
| 31 de diciembre de 2022 | $-32.12 | $-33.32 | 3.6% | |
| 31 de marzo de 2022 | $-2.92 | $-3.03 | 3.6% |
Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja
Estado de resultados
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6M | $0 | · | · | · | · | · | · | · | |
| R&D Expense | · | · | · | · | · | $15M | $26M | $20M | $16M | $9M | |
| SG&A Expense | $3M | $5M | $9M | $11M | $20M | $15M | $24M | $26M | $3M | $854.0K | |
| Operating Expenses | $6M | $9M | $17M | $34M | $66M | $33M | $51M | $48M | $20M | $10M | |
| Operating Income | $-6M | $-2M | $-17M | $-34M | $-66M | $-33M | $-51M | $-48M | $-20M | $-10M | |
| Other Non-op | $443.0K | $-675.0K | $234.0K | $-2M | $-709.0K | $-1M | $-319.0K | $502.0K | $-824.0K | $-7.0K | |
| Pretax Income | $-6M | $-3M | $-17M | $-36M | $-67M | $-35M | $-51M | $-47M | $-21M | $-10M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $122.0K | · | · | |
| Net Income | $-6M | $-3M | $-17M | $-36M | $-67M | $-35M | $-51M | $-47M | $-21M | $-10M | |
| EPS (Basic) | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 | · | · | · | · | · | |
| EPS (Diluted) | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 | · | · | · | · | · | |
| Shares (Basic) | 12,347,495 | 3,758,804 | 2,570,620 | 2,166,311 | 1,749,071 | · | · | · | · | · | |
| Shares (Diluted) | 12,347,495 | 3,758,804 | 2,570,620 | 2,166,311 | 1,749,071 | · | · | · | · | · | |
| EBITDA | $-6M | · | · | $-34M | $-66M | $-33M | $-51M | $-48M | · | · |
Balance general
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5M | $111.0K | $1M | $19M | $42M | $25M | $22M | $49M | $24M | $2M | |
| Prepaid Expense | $479.0K | $142.0K | $194.0K | $661.0K | $913.0K | $1M | $1M | $2M | $355.0K | $837.0K | |
| Current Assets | $5M | $3M | $2M | $20M | $43M | $26M | $58M | $50M | $25M | $3M | |
| PP&E (Net) | $0 | $0 | $35.0K | $169.0K | $216.0K | $133.0K | $201.0K | $248.0K | $278.0K | $41.0K | |
| PP&E (Gross) | $0 | $0 | $313.0K | $349.0K | $387.0K | $446.0K | $488.0K | $452.0K | $332.0K | $56.0K | |
| Accum. Depreciation | $0 | $0 | $278.0K | $180.0K | $171.0K | $313.0K | $287.0K | $204.0K | $54.0K | $15.0K | |
| Other Non-current Assets | · | · | · | · | · | $30.0K | $113.0K | $129.0K | · | · | |
| Total Assets | $5M | $3M | $2M | $21M | $45M | $26M | $59M | $51M | $25M | $3M | |
| Accounts Payable | $3M | $5M | $6M | $3M | $1M | $481.0K | $2M | $747.0K | $2M | $2M | |
| Accrued Liabilities | $2M | $1M | $1M | $3M | $4M | $3M | $5M | $7M | $2M | $619.0K | |
| Current Liabilities | $17M | $27M | $23M | $23M | $10M | $10M | $12M | $8M | $3M | $3M | |
| Capital Leases | $0 | $0 | $2.0K | $135.0K | $804.0K | $33.0K | $425.0K | · | · | · | |
| Total Liabilities | $17M | $27M | $24M | $32M | $23M | $16M | $23M | $8M | · | · | |
| Long-term Debt | $1M | $7M | $4M | $12M | $11M | $11M | $14M | · | · | · | |
| Total Debt | $1M | · | · | $13M | $12M | $12M | $15M | · | · | · | |
| Common Stock | $4.0K | $35.0K | $31.0K | $22.0K | $22.0K | $404.0K | $402.0K | $360.0K | $274.0K | $42.0K | |
| Retained Earnings | $-301M | $-295M | $-291M | $-274M | $-238M | $-172M | $-137M | $-86M | $-39M | $-18M | |
| Treasury Stock | · | · | · | $0 | $2M | $2M | $2M | $1M | · | · | |
| AOCI | · | · | · | · | · | · | $18.0K | · | · | · | |
| Stockholders' Equity | $-12M | $-24M | $-23M | $-11M | $22M | $10M | $36M | $43M | $21M | $610.0K | |
| Liabilities + Equity | $5M | $3M | $2M | $21M | $45M | $26M | $59M | $51M | $25M | $3M | |
| Shares Outstanding | 435,432 | 321,252 | 3,143,390 | 2,166,356 | 2,166,248 | 1,003,930 | 40,030,763 | 35,860,114 | 27,527,738 | 4,205,278 |
Flujo de Efectivo
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $235.0K | $541.0K | $2M | $3M | $9M | $9M | $11M | $13M | $101.0K | $78.0K | |
| Deferred Tax | · | · | · | · | · | · | · | · | $10M | · | |
| Restructuring | · | · | · | · | · | $2M | · | · | · | · | |
| Operating Cash Flow | $-6M | $-5M | $-14M | $-32M | $-35M | $-28M | $-39M | $-31M | $-16M | $-9M | |
| CapEx | · | · | · | $66.0K | $89.0K | · | $40.0K | $235.0K | $237.0K | $36.0K | |
| Investing Cash Flow | $1.0K | $38.0K | $309.0K | $-66.0K | $2M | $34M | $-34M | $-317.0K | $-114.0K | $-36.0K | |
| Debt Issued | $3M | $4M | $0 | $0 | $12M | $797.0K | $15M | · | · | · | |
| Net Debt Issued | $3M | · | · | $0 | $12M | $797.0K | $15M | · | · | · | |
| Stock Issued | $0 | $0 | $3M | $0 | $48M | · | $710.0K | $2M | $17M | · | |
| Net Stock Activity | $0 | · | · | $0 | · | · | · | · | · | · | |
| Dividends Paid | · | · | · | · | · | · | $0 | $0 | $0 | · | |
| Financing Cash Flow | $11M | $3M | $-4M | $9M | $51M | $-3M | $47M | $56M | $38M | $10M | |
| Net Change in Cash | $5M | $-1M | $-18M | $-23M | $18M | $2M | $-26M | $24M | $22M | $856.0K | |
| Taxes Paid | · | · | · | · | · | $5.0K | $36.0K | · | · | · | |
| Free Cash Flow | · | · | · | $-32M | $-35M | · | $-39M | $-32M | · | · |
Rentabilidad
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -145.4% | · | · | -108.9% | -186.3% | -81.0% | -92.8% | -125.0% | · | · | |
| ROE | 30.1% | · | · | 461.1% | -241.0% | -273.2% | -124.9% | -100.0% | · | · | |
| ROIC | 59.0% | · | · | -1833.7% | -192.0% | -153.2% | -99.0% | -111.1% | · | · |
Liquidez y Solvencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.3 | · | · | 0.9 | 4.4 | 2.6 | 4.9 | 6.4 | · | · | |
| Quick Ratio | 0.3 | · | · | 0.8 | 4.2 | 2.5 | 1.9 | 6.2 | · | · | |
| Debt / Equity | -0.1 | · | · | -1.2 | 0.5 | 1.1 | 0.4 | · | · | · | |
| LT Debt / Equity | 0.0 | · | · | -0.8 | 0.5 | 0.6 | 0.3 | · | · | · |
Eficiencia
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | · | · | · | · | · | · | · | · | · |
Por Acción
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-2.49 | · | · | $-4.92 | $0.26 | $0.25 | $0.90 | $1.20 | · | · | |
| Revenue / Share | $0.00 | · | · | · | · | · | · | · | · | · | |
| Cash Flow / Share | $-0.51 | · | · | $-14.70 | · | · | · | · | · | · | |
| Cash / Share | $1.00 | · | · | $8.87 | $0.49 | $0.61 | $0.56 | $1.36 | · | · | |
| EPS (TTM) | $-0.49 | · | · | $-16.65 | $-38.15 | · | · | · | · | · |
Valoración (TTM)
| Métrica | Tendencia | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $0 | · | · | · | · | · | · | · | · | · | |
| Net Income TTM | $-6M | · | · | $-36M | $-67M | $-35M | $-51M | $-47M | $-21M | · | |
| Payout Ratio | · | · | · | · | · | · | 0.00% | 0.00% | · | · | |
| Annual Payout | · | · | · | · | · | · | $0 | $0 | $0 | · |
Estado de resultados
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SG&A Expense | $2M | $2M | · | $684.0K | $712.0K | · | $3M | $2M | $2M | $2M | $3M | $2M | $3M | $3M | $4M | $5M | |
| Operating Expenses | $4M | $4M | · | $2M | $1M | · | $4M | $4M | $4M | $5M | $6M | $7M | $10M | $11M | $12M | $10M | |
| Operating Income | $-4M | $-4M | · | $-2M | $-1M | · | $-4M | $-4M | $-4M | $-5M | $-6M | $-7M | $-10M | $-11M | $-12M | $-10M | |
| Other Non-op | $-52.0K | $41.0K | · | $-309.0K | $-487.0K | · | $1M | $45.0K | $-201.0K | $-747.0K | $-291.0K | $-366.0K | $-322.0K | $-667.0K | $-460.0K | $360.0K | |
| Net Income | $-5M | $-4M | · | $-2M | $-2M | · | $-3M | $-4M | $-4M | $-6M | $-6M | $-8M | $-11M | $-12M | $-12M | $-10M | |
| EPS (Basic) | $-0.66 | $-0.08 | · | $-5.45 | $-0.45 | · | $-0.48 | $-1.31 | $-1.96 | $-2.88 | $-2.92 | $-3.47 | $-4.90 | $-5.36 | $-37.30 | $-0.11 | |
| EPS (Diluted) | $-0.66 | $-0.08 | · | $-5.45 | $-0.45 | · | $-0.48 | $-1.31 | $-1.96 | $-2.88 | $-2.92 | $-3.47 | $-4.90 | $-5.36 | $-37.30 | $-0.11 | |
| Shares (Basic) | 6,789,165 | 48,210,071 | · | 347,000 | 3,805,550 | · | · | 2,747,687 | 2,212,364 | 2,166,356 | · | 2,166,404 | 2,166,352 | 2,166,275 | · | 86,208,754 | |
| Shares (Diluted) | 6,789,165 | 48,210,071 | · | 347,000 | 3,805,550 | · | · | 2,747,687 | 2,212,364 | 2,166,356 | · | 2,166,404 | 2,166,352 | 2,166,275 | · | 86,208,754 | |
| EBITDA | $-4M | $-4M | · | · | · | · | · | $-4M | $-4M | $-5M | · | $-7M | $-10M | $-11M | · | $-10M |
Balance general
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $62M | $6M | $5M | · | · | $111.0K | $1M | $5M | $4M | $5M | $19M | $25M | $30M | $40M | $42M | $52M | |
| Prepaid Expense | $1M | $2M | $479.0K | · | · | $142.0K | $194.0K | $635.0K | $841.0K | $1M | $661.0K | $854.0K | $1M | $2M | $913.0K | $864.0K | |
| Current Assets | $63M | $9M | $5M | · | · | $3M | $2M | $6M | $5M | $6M | $20M | $26M | $32M | $42M | $43M | $54M | |
| PP&E (Net) | · | · | $0 | · | · | $0 | $35.0K | $107.0K | $130.0K | $143.0K | $169.0K | $215.0K | $190.0K | $206.0K | $216.0K | $224.0K | |
| PP&E (Gross) | · | · | $0 | · | · | $0 | $313.0K | · | · | $331.0K | $349.0K | $386.0K | $338.0K | $398.0K | $387.0K | $368.0K | |
| Accum. Depreciation | · | · | $0 | · | · | $0 | $278.0K | · | · | $188.0K | $180.0K | $171.0K | $148.0K | $192.0K | $171.0K | $144.0K | |
| Total Assets | $63M | $9M | $5M | · | · | $3M | $2M | $6M | $6M | $7M | $21M | $27M | $33M | $44M | $45M | $55M | |
| Accounts Payable | $3M | $3M | $3M | · | · | $5M | $6M | $3M | $3M | $2M | $3M | $2M | $2M | $3M | $1M | $3M | |
| Accrued Liabilities | $2M | $1M | $2M | · | · | $1M | $1M | $2M | $3M | $2M | $3M | $5M | $5M | $5M | $4M | $3M | |
| Current Liabilities | $17M | $16M | $17M | · | · | $27M | $23M | $23M | $21M | $19M | $23M | $22M | $20M | $19M | $10M | $10M | |
| Capital Leases | · | · | $0 | · | · | $0 | $2.0K | $3.0K | $4.0K | $6.0K | $135.0K | $318.0K | $496.0K | $638.0K | $804.0K | $964.0K | |
| Total Liabilities | · | · | $17M | · | · | $27M | $24M | $26M | $25M | $23M | $32M | $32M | $31M | $32M | $23M | $22M | |
| Long-term Debt | · | · | $1M | · | · | $7M | $4M | $5M | $5M | $5M | $12M | $12M | $11M | $11M | $12M | $11M | |
| Total Debt | $0 | $0 | · | · | · | · | · | $5M | $6M | $6M | · | $12M | $12M | $12M | · | $12M | |
| Common Stock | $40.0K | $51.0K | $48.0K | · | · | $35.0K | $31.0K | $31.0K | $25.0K | $22.0K | $22.0K | $871.0K | $871.0K | $871.0K | $22.0K | $863.0K | |
| Retained Earnings | $-309M | $-304M | $-301M | · | · | $-295M | $-291M | $-289M | $-285M | $-281M | $-274M | $-268M | $-261M | $-250M | $-238M | $-226M | |
| Treasury Stock | · | · | · | · | · | · | · | · | · | · | $0 | $2M | $2M | $2M | $2M | $2M | |
| Stockholders' Equity | $46M | $-8M | $-12M | · | · | $-24M | $-23M | $-20M | $-19M | $-16M | $-11M | $-5M | $2M | $12M | $22M | $33M | |
| Liabilities + Equity | $63M | $9M | $5M | · | · | $3M | $2M | $6M | $6M | $7M | $21M | $27M | $33M | $44M | $45M | $55M | |
| Shares Outstanding | 4,036,398 | 5,072,935 | 4,790,239 | · | · | 3,534,250 | 3,143,390 | 2,166,356 | 2,166,356 | 2,166,356 | 2,166,356 | 86,656,221 | 86,656,221 | 86,653,089 | 2,166,248 | 86,252,365 |
Flujo de Efectivo
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $95.0K | $46.0K | · | $16.0K | $20.0K | · | $340.0K | $418.0K | $610.0K | $597.0K | $641.0K | $714.0K | $744.0K | $922.0K | $2M | $2M | |
| Operating Cash Flow | $-5M | $-5M | · | $-2M | $1M | · | $-2M | $-3M | $-2M | $-7M | $-6M | $-7M | $-10M | $-9M | $-10M | $-8M | |
| CapEx | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $48.0K | $7.0K | $11.0K | $20.0K | · | |
| Investing Cash Flow | · | · | · | · | · | · | $51.0K | $233.0K | $14.0K | $11.0K | $0 | $-48.0K | $-7.0K | $-11.0K | $-20.0K | $-69.0K | |
| Debt Issued | $0 | $0 | · | $2M | $390.0K | · | · | · | · | · | $0 | · | · | · | $-36.0K | · | |
| Net Debt Issued | · | $0 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | · | · | · | · | $0 | $2M | $1M | · | $0 | $0 | · | · | $0 | $0 | |
| Net Stock Activity | · | · | · | · | · | · | · | $2M | $1M | · | · | · | · | · | · | · | |
| Financing Cash Flow | $60M | $7M | · | $2M | $-865.0K | · | $-2M | $4M | $1M | $-8M | $312.0K | $2M | $0 | $7M | $-160.0K | $3M | |
| Net Change in Cash | $56M | $2M | · | $122.0K | $339.0K | · | $-4M | $453.0K | $-624.0K | $-14M | $-5M | $-5M | $-10M | $-3M | $-10M | $-4M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-7M | · | · | · | $-10M | · | · |
Rentabilidad
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -13.0% | -47.8% | · | · | · | · | · | -21.8% | -22.3% | -24.5% | · | -18.2% | -22.7% | -36.3% | · | -22.4% | |
| ROE | -32.4% | 31.4% | · | · | · | · | · | 28.7% | 51.7% | 270.5% | · | -53.6% | -50.0% | -161.0% | · | -41.1% |
Liquidez y Solvencia
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.7 | 0.5 | · | · | · | · | · | 0.2 | 0.3 | 0.3 | · | 1.2 | 1.6 | 2.2 | · | 5.6 | |
| Quick Ratio | 3.7 | 0.4 | · | · | · | · | · | 0.2 | 0.2 | 0.3 | · | 1.1 | 1.5 | 2.1 | · | 5.5 | |
| Debt / Equity | 0.0 | 0.0 | · | · | · | · | · | -0.3 | -0.3 | -0.3 | · | -2.5 | 6.8 | 1.0 | · | 0.4 | |
| LT Debt / Equity | · | · | · | · | · | · | · | -0.1 | -0.2 | -0.2 | · | -2.0 | 6.1 | 1.0 | · | 0.4 |
Por Acción
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $11.50 | $-1.50 | · | · | · | · | · | $-9.25 | $-8.58 | $-7.52 | · | $-0.06 | $0.02 | $0.13 | · | $0.38 | |
| Cash Flow / Share | · | $-0.11 | · | · | · | · | · | · | · | $-3.15 | · | · | · | · | · | · | |
| Cash / Share | $15.35 | $1.25 | · | · | · | · | · | $2.20 | $2.00 | $2.26 | · | $0.28 | $0.35 | $0.46 | · | $0.61 | |
| EPS (TTM) | · | · | · | · | · | · | · | $-9.07 | $-11.23 | $-14.17 | · | $-51.03 | $-47.67 | $-43.31 | · | · |
Valoración (TTM)
| Métrica | Tendencia | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | · | · | · | · | · | · | · | $-20M | $-24M | $-31M | · | $-42M | $-44M | $-70M | · | $-61M | |
| Market Cap | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $-6M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 1.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 1.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
Período más reciente a la izquierda · valores nulos mostrados como ·
Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Ingresos | $0 | $6M | $0 | · | · |
| Beneficio neto | $-6M | $-3M | $-17M | $-36M | $-67M |
| EPS Diluido | $-0.49 | $-0.84 | $-6.63 | $-16.65 | $-38.15 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Deuda / Patrimonio | -0.1 | · | · | -1.2 | 0.5 |
| Ratio corriente | 0.3 | · | · | 0.9 | 4.4 |
| Ratio Rápido | 0.3 | · | · | 0.8 | 4.2 |
| Métrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flujo de caja libre | · | · | · | $-32M | $-35M |
Activistas y propietarios del %+ 5 21 tenencias
Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.
| Declarante | Presentado | Participación | Estado | Propósito | Presentación |
|---|---|---|---|---|---|
| Advent Life Sciences LLP, Advent Life Sciences Fund II LP, Rajesh Parekh, Shahzad Malik, Kaasim Mahmood, Dominic Schmidt ×2 presentaciones | 20 de agosto de 2024 | · | Enmienda | · | SEC |
| LSP V Coöperatieve U.A, LSP V Management B.V. ×2 presentaciones | 3 de febrero de 2022 | · | Enmienda | · | SEC |
| Pontifax Management III G.P. (2011) Ltd., Pontifax Management Fund III L.P., Pontifax (Cayman) III, L.P., Pontifax (Israel) III, L.P., Pontifax Management 4 G.P. (2015) Ltd., Pontifax IV GP L.P., Pontifax (Cayman) IV L.P., Pontifax (Israel) IV L.P., Pontifax (China) IV L.P., Pontifax Late Stage GP Ltd., Pontifax Late Stage Fund L.P. ×4 presentaciones | 21 de mayo de 2021 | · | Enmienda | · | SEC |
| LSP V Coöperatieve U.A., LSP V Management B.V. | 29 de diciembre de 2017 | · | Presentación inicial | · | SEC |
| Dr. Phillip Frost, Frost Gamma Investments Trust ×6 presentaciones | 27 de diciembre de 2017 | · | Enmienda | Campaña de la junta directiva | SEC |
| Vaughn Smider, M.D., Ph.D. ×2 presentaciones | 19 de junio de 2014 | · | Enmienda | · | SEC |
| Christopher Forbes ×3 presentaciones | 19 de enero de 2012 | · | Enmienda | Inversión pasiva | SEC |
| John E. Thompson, Ph.D. | 14 de febrero de 2005 | · | Enmienda | · | SEC |
| Persona informante no revelada | 18 de febrero de 2003 | · | Enmienda | · | SEC |
| Persona informante no revelada | 14 de febrero de 2003 | · | Enmienda | · | SEC |
| Persona informante no revelada | 14 de febrero de 2003 | · | Enmienda | · | SEC |
| Persona informante no revelada | 12 de febrero de 2003 | · | Enmienda | Inversión pasiva | SEC |
| Persona informante no revelada | 28 de marzo de 2002 | · | Enmienda | · | SEC |
| Persona informante no revelada | 13 de febrero de 2002 | · | Enmienda | · | SEC |
| Persona informante no revelada | 13 de febrero de 2002 | · | Enmienda | · | SEC |
| Persona informante no revelada | 13 de febrero de 2002 | · | Enmienda | · | SEC |
| Persona informante no revelada | 10 de enero de 2002 | · | Presentación inicial | Inversión pasiva | SEC |
| Persona informante no revelada, Persona informante no revelada | 2 de enero de 2002 | · | Presentación inicial | · | SEC |
| Persona informante no revelada | 14 de febrero de 2001 | · | Enmienda | · | SEC |
| Persona informante no revelada | 14 de febrero de 2001 | · | Presentación inicial | · | SEC |
| Persona informante no revelada | 14 de febrero de 2001 | · | Enmienda | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Informantes de la empresa 47 insiders · 16 directivos · 23 consejeros
| Insider | Rol | Última actividad | Acciones en propiedad | Compras 12m | Ventas 12m | Neto 12m |
|---|---|---|---|---|---|---|
| Sumit Aggarwal | President and CEO | 10 de junio de 2026 A | 1 672 756 | 0 | 0 | $0 |
| Gregory C. Williams | CHIEF EXECUTIVE OFFICER | 25 de febrero de 2021 M | 44 629 | 0 | 0 | $0 |
| Ron Martell | Chief Executive Officer | 18 de noviembre de 2014 A | · | 0 | 0 | $0 |
| Daniel E. Geffken | INTERIM CFO | 29 de noviembre de 2021 P | 50 000 | 0 | 0 | $0 |
| Joel Brooks | Chief Financial Officer | 18 de noviembre de 2014 A | 90 875 | 0 | 0 | $0 |
| Leslie J Browne | President | 18 de noviembre de 2014 A | 1 290 | 0 | 0 | $0 |
| Neil S. Belloff | COO, GENERAL COUNSEL &CORP SEC | 30 de julio de 2021 M | 32 699 | 0 | 0 | $0 |
| Vijay Modur | HEAD OF R&D | 25 de enero de 2023 A | 154 953 | 0 | 0 | $0 |
| Stephen G. Macdonald | VP FINANCE & ACCTG, TREASURER | 12 de febrero de 2021 A | · | 0 | 0 | $0 |
| Pedro Huertas | Chief Medical Officer | 16 de mayo de 2018 A | 137 725 | 0 | 0 | $0 |
| Miguel De Los Rios | VP - Research | 18 de noviembre de 2014 A | · | 0 | 0 | $0 |
| James Joseph Graziano | Chief Technology Officer | 18 de noviembre de 2014 A | 104 386 | 0 | 0 | $0 |
| Vaughn Smider | Chief Scientific Officer | 18 de noviembre de 2014 A | 1 058 970 | 0 | 0 | $0 |
| Richard S Dondero | VP - Preclinical Research | 18 de noviembre de 2014 A | · | 0 | 0 | $0 |
| John Thompson PHD | Scientific Founder | 18 de noviembre de 2014 A | · | 0 | 0 | $0 |
| Sascha P Fedyszyn | VP - Corporate Dev. | 19 de noviembre de 2009 D | 153 460 | 0 | 0 | $0 |
| Alan Edmund Walts | Consejero | 8 de junio de 2026 A | 15 567 | 0 | 0 | $0 |
| Stephen W Webster | Consejero | 8 de junio de 2026 A | · | 0 | 0 | $0 |
| Nina S Kjellson | Consejero | 8 de junio de 2026 A | · | 0 | 0 | $0 |
| Steven D Rubin | Consejero | 8 de junio de 2026 A | 14 625 | 0 | 0 | $0 |
| Lindsay Androski | Consejero | 24 de enero de 2025 M | 15 750 | 0 | 0 | $0 |
| Tomer Kariv | Consejero | 30 de enero de 2023 A | 616 592 | 0 | 0 | $0 |
| Jasbir Seehra | Consejero | 15 de junio de 2022 A | · | 0 | 0 | $0 |
| Zafrira Avnur | Consejero | 15 de junio de 2022 A | 2 263 | 0 | 0 | $0 |
| Gadi Veinrib | Consejero | 15 de junio de 2022 A | · | 0 | 0 | $0 |
| Ran Nussbaum | Consejero | 15 de junio de 2022 A | 616 592 | 0 | 0 | $0 |
| Rajesh R Parekh | Consejero | 15 de junio de 2022 A | 4 827 129 | 0 | 0 | $0 |
| Martijn Kleijwegt | Consejero | 20 de mayo de 2020 A | 2 953 673 | 0 | 0 | $0 |
| Silvia Noiman | Consejero | 20 de mayo de 2020 A | 490 789 | 0 | 0 | $0 |
| Harlan Waksal | Consejero | 19 de noviembre de 2015 A | 2 805 750 | 0 | 0 | $0 |
| Christopher Forbes | Consejero | 18 de noviembre de 2014 A | 12 757 318 | 0 | 0 | $0 |
| Warren John Isabelle | Consejero | 16 de mayo de 2014 A | 6 038 | 0 | 0 | $0 |
| Jack Van Hulst | Consejero | 16 de mayo de 2014 A | 40 068 | 0 | 0 | $0 |
| Thomas C Quick | Consejero | 16 de mayo de 2014 A | 13 149 | 0 | 0 | $0 |
| Ruedi Stalder | Consejero | 16 de mayo de 2014 A | 1 053 938 | 0 | 0 | $0 |
| Domicilium Real Estate Fund III LP | Propietario del 10% | 10 de junio de 2026 J | 361 578 | 0 | 0 | $0 |
| Coastlands Capital LP | Propietario del 10% | 27 de mayo de 2026 J | 0 | 0 | 0 | $0 |
| Gilad Shabtai | Propietario del 10% | 30 de abril de 2018 P | 3 351 770 | 0 | 0 | $0 |
| Opko Health, Inc. | Propietario del 10% | 19 de diciembre de 2017 A | 1 289 818 | 0 | 0 | $0 |
| Paul Edward Klaver | Propietario del 10% | 22 de marzo de 2012 G | 10 146 527 | 0 | 0 | $0 |
| Gregory L Weaver | · | 15 de marzo de 2020 M | 10 431 | 0 | 0 | $0 |
| Robert Ward | · | 29 de febrero de 2020 M | 244 267 | 0 | 0 | $0 |
| David P. Snow | · | 30 de enero de 2020 M | 4 205 | 0 | 0 | $0 |
| John N Braca | · | 19 de diciembre de 2017 A | 137 964 | 0 | 0 | $0 |
| David Rector | · | 19 de diciembre de 2017 A | 352 785 | 0 | 0 | $0 |
| Phillip Frost, M.D. | · | 19 de diciembre de 2017 A | · | 0 | 0 | $0 |
| Bruce C Galton | · | 1 de diciembre de 2009 S | 98 450 | 0 | 0 | $0 |
Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto
Propiedad de ETFs Mantenido por 2 ETFs
El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.
ELOX Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista
calificación · 9 analistas
COMPRA
Objetivo mediano
$39.00
+151,5%
3 33,3%
Compra fuerte
5 55,6%
Compra
1 11,1%
Mantener
0 0,0%
Venta
0 0,0%
Venta fuerte
Precio objetivo a 12 meses
4 analistas · 2026-09-28Objetivo medio $38.25 +146,6%
← Por Debajo de Todos los Objetivos
Precio Actual $15.51
Mín$32.00
Media$38.25
Máx$43.00
Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector
Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.
| Ticker | Capitalización Bursátil | P/E | Ingresos interanuales | Margen Neto | ROE | Margen Bruto |
|---|---|---|---|---|---|---|
| ELOX | · | · | · | · | 30.1% | · |
| TELO | $46M | -4.0 | · | · | -325.7% | · |
| VRCA | $143M | -4.9 | 370.2% | -50.3% | -492.8% | · |
| RFL | · | -1.6 | 44.0% | -3328.2% | -34.6% | · |
| CING | · | · | · | · | · | · |
| PLRX | $75M | -0.5 | -83.7% | · | -74.4% | · |
| HYPD | $31M | -0.4 | 1318.8% | -5570.6% | -115.6% | 62.7% |
| TLPH | $56M | · | · | -51035.7% | -120.8% | · |
| IMA | · | -0.7 | -77.1% | -5668.6% | 192.1% | · |
Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos
Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.
Tu selección se guarda y te sigue en todos los tickers.
Fuente: SEC 10-Q presentada el Ago 11, 2026